Topiramate in migraine prophylaxis

被引：14

作者：

D'Amico, D

Grazzi, L

Usai, S

Moschiano, F

Bussone, G

机构：

[1] Ist Nazl Neurol Carlo Besta, UO Cefalee & Malattie Cerebrovasc, I-20133 Milan, Italy

[2] L Mandic Hosp, Merate, LC, Italy

来源：

NEUROLOGICAL SCIENCES | 2005年 / 26卷 / Suppl 2期

关键词：

migraine; topiramate; prophylaxis; clinical trial; clinical practice;

D O I：

10.1007/s10072-005-0425-6

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

This paper reviews results of placebo-controlled trials on topiramate (TPM) prophylaxis in migraine patients, and discusses issues regarding the use of this medication in clinical practice. Data from well conducted double-blind controlled trials and from a comparative trial show that TPM is effective against migraine, confirming the experience of physicians in various countries. Lack of major contraindications, high responder rate, good tolerability at the target dose (100 mg/day) following slow titration, and lack of weight gain make TPM one of the most effective and well accepted drugs for migraine prophylaxis.

引用

页码：S130 / S133

页数：4

共 18 条

[1]

[Anonymous], PRACT GUID ID EV TRE

[2] Topiramate for migraine prevention - A randomized controlled trial [J].